TG Therapeutics Inc [NASDAQ: TGTX] loss -17.99% on the last trading session, reaching $28.72 price per share at the time.
TG Therapeutics Inc represents 158.75 million in outstanding shares, while the company has a total market value of $4.56 billion with the latest information. TGTX stock price has been found in the range of $28.28 to $32.1999.
If compared to the average trading volume of 2.04M shares, TGTX reached a trading volume of 11434936 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TG Therapeutics Inc [TGTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $40.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for TG Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 10, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on October 29, 2024, representing the official price target for TG Therapeutics Inc stock. Previously, the target price had yet another drop from $16 to $12, while Goldman kept a Neutral rating on TGTX stock. On June 26, 2023, analysts decreased their price target for TGTX shares from 55 to 40.
The Price to Book ratio for the last quarter was 19.14, with the Price to Cash per share for the same quarter was set at 1.76.
Trading performance analysis for TGTX stock
TG Therapeutics Inc [TGTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.20. With this latest performance, TGTX shares dropped by -21.79% in over the last four-week period, additionally sinking by -9.40% over the last 6 months – not to mention a drop of -4.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 24.62, with the RSI for the last a single of trading hit 2.06, and the three-weeks RSI is set at 1.78 for TG Therapeutics Inc [TGTX]. The present Moving Average for the last 50 days of trading for this stock 36.63, while it was recorded at 34.17 for the last single week of trading, and 34.10 for the last 200 days.
TG Therapeutics Inc [TGTX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and TG Therapeutics Inc [TGTX] shares currently have an operating margin of 18.91% and a Gross Margin at 86.96%. TG Therapeutics Inc’s Net Margin is presently recorded at 13.31%.
TG Therapeutics Inc (TGTX) Capital Structure & Debt Analysis
According to recent financial data for TG Therapeutics Inc. ( TGTX), the Return on Equity (ROE) stands at 26.63%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 10.95%, reflecting the company’s efficiency in generating profits from its assets. Additionally, TG Therapeutics Inc’s Return on Invested Capital (ROIC) is 12.34%, showcasing its effectiveness in deploying capital for earnings.
TG Therapeutics Inc (TGTX) Efficiency & Liquidity Metrics
Based on TG Therapeutics Inc’s (TGTX) latest financial statements, the Debt-to-Equity Ratio is 0.92%, indicating its reliance on debt financing relative to shareholder equity.
TG Therapeutics Inc (TGTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, TG Therapeutics Inc. (TGTX) effectively leverages its workforce, generating an average of $178875.74 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.02% and a Quick Ratio of 3.04%, indicating strong ability to cover short-term liabilities.
TG Therapeutics Inc [TGTX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TG Therapeutics Inc go to 150.68%.
An analysis of Institutional ownership at TG Therapeutics Inc [TGTX]
There are presently around $63.27%, or 70.10% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 13.69 million shares, which is approximately 9.4603%. BLACKROCK INC., holding 11.39 million shares of the stock with an approximate value of $$202.6 million in TGTX stocks shares; and BLACKROCK INC., currently with $$119.12 million in TGTX stock with ownership which is approximately 4.6267%.
